Skip to content

Exogenous surfactant obtained from goat lungs for treating respiratory difficulty due to lack of surfactant in preterm neonates

Evaluating the Efficacy and Safety of an Innovative and Affordable Goat Lung Surfactant for the treatment of Respiratory Distress Syndrome (RDS) in preterm neonates: a multi-site randomized clinical trial

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/07/005968
Enrollment
900
Registered
2015-07-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Preterm neonates with Respiratory Distress Syndrome

Interventions

Intervention1: Goat lung surfactant extract: Intratracheal administration in dose of 100 mg/kg to be administered as a single dose over 5 to 10 minutes once the baby meets the criteria of respiratory

Sponsors

All India Institute of Medical Sciences New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Neonates born at the study sites and fulfilling all of the following criteria will be eligible for enrolment in the study 1. Gestational age less than or equal to 32 completed weeks 2. Onset of respiratory distress within six hours of age 3. If baby meets criteria for surfactant replacement therapy: a. FiO2 needed is 40% or higher while the baby is on CPAP to maintain pre-ductal oxygen saturation between 90% to 95% or b. Baby needs intubation because of CPAP failure or severe respiratory distress (Chest X-ray is not mandatory for deciding the need for SRT).

Exclusion criteria

Exclusion criteria: Neonates with any of the following criteria will be excluded: 1.Gestation below 26 wk 2.Babies with severe birth asphyxia as defined by the need for chest compressions and/or initial (umbilical arterial/or within 1 hour of birth) pH 3. Major congenital malformations 4. Prophylactic surfactant administration, i.e. administration of surfactant before the infant develops respiratory distress 5.Air leak or pulmonary hemorrhage prior to enrollment 6.Shock requiring vasopressor support prior to enrollment

Design outcomes

Primary

MeasureTime frame
BPD free survivalTimepoint: 36 weeks of post-menstrual age which means an postnatal age of 4 to 10 weeks after birth.

Secondary

MeasureTime frame
Any air leak within 72 hours of administration of surfactantTimepoint: Occurrence of any airleak -pneumothorax, PIE or pneumomediastinum in chest X-ray (done when clinically suspected);Area under the curve for (AUC) for oxygen requirement (FiO2) requirement in first 48 hTimepoint: The oxygen requirement will be recorded every hour using a standardized protocol and AUC for first 48 hrs will be calculated;Duration of hospital stayTimepoint: until discharge;Duration of mechanical ventilation and CPAPTimepoint: Cumulative duration of mechanical ventilation and CPAP until discharge/death;IVH grade 3 or 4Timepoint: At 72±24 hrs after birth;Neonatal mortalityTimepoint: Death of a neonate in first 28 days of life;Pulmonary hemorrhageTimepoint: Occurrence of bleeding/blood stained secretions from the trachea within 48 hr of surfactant administration;PVL-cystic and non-cysticTimepoint: Ultrasonography would be carried out by a radiologist/neonatologist at 72±24 hrs, 28±7days;Respiratory support at 72 h and 7 days of ageTimepoint: 72 hours and 7 days of age;Retinopathy of prematurity (ROP)Timepoint: Eyes of the babies would be examined by the ophthalmologists starting from 4 wk of life;SepsisTimepoint: Occurrence of any episode of sepsis (culture positive or culture negative) from the time of enrolment until 7 days of age

Countries

India

Contacts

Public ContactRamesh Agarwal

All India Institute of Medical Sciences

ra.aiims@gmail.com26589633

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026